Intervening early with lenalidomide for multiple myeloma (MM) could delay progression to symptomatic disease. A randomized trial assessed the efficacy of single-agent lenalidomide compared with observation in patients with intermediate- or high-risk smoldering multiple myeloma, and lenalidomide significantly delays said progression.

Reference:  Lonial S, Jacobus S, Fonseca R, Weiss M, et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol. 2020 Apr 10;38(11):1126-1137. doi: 10.1200/JCO.19.01740. Epub 2019 Oct 25. PMID: 31652094; PMCID: PMC7145586.